GSK tax dispute
Executive Summary
GlaxoSmithKline receives Internal Revenue Service notice of deficiency for $1.9 bil. in taxes for years 1997-2000. "GSK disagrees with this tax claim, and the company believes that it has paid all the taxes owed to the U.S. government for these years," GSK said. The company received a separate notice of deficiency in 2004 for $2.7 bil. in taxes for 1989-1996 (1"The Pink Sheet" Jan. 12, 2004, p. 40). The claims are related to allocation of taxes on profits for heritage company Glaxo Wellcome products, GSK says. The company will ask U.S. tax court to consolidate 1997-2000 claim with case pending for the 1989-1996 tax years; a provisional trial date is set for October 2006. GSK estimates interest owed on the two claims would total $3.2 bil. net of federal tax relief if IRS is successful...
You may also be interested in...
GSK Contests $5.2 Bil. Tax Bill After IRS Decision On Zantac Transfer Pricing
GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.